Hesperidin (SHINJIMUN) blood perfusion trial

A double-blind placebo-controlled crossover study of Hesperidin from fermented Shekwasa (SHINJIMUN) on Peripheral Blood Perfusion

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071200042

Enrollment

Registered

2020-10-13

Start date

2020-10-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Arm A:Fermented Shekwasa (SHINJIMUN) 4 tabs/day given on day 1 to 7 and then Placebo 4 tab/day given on day 8 to 14. Arm B:Placebo 4 tabs/day given on day 1 to 8 then ermented Shekwasa (SHINJIMUN) 4 t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male and female patients, 20-70 years old 2. Written informed consent 3. For participants taking medications (including supplements and dietary supplements), those who have not changed their dosage and administration during the study period

Exclusion criteria

Exclusion criteria: 1. Renal dysfunction (eGFR<30ml/min/1.73m2) 2. Liver cirrhosis 3. Clinical evidence of cholestasis 4. Active cancer 5. Pregnant or lactating female 6. Participant deemed inadequate to this study

Design outcomes

Primary

Measure	Time frame
Amount of Peripheral blood perfusion (ml/min)	—

Secondary

Measure	Time frame
1. Serum Hesperetin concentration 2. Intracranial SpO2 (%) 3. Serum Hexanoyl Lysine concentration 4. Stool 5. Serum Triglyceride level	—

Contacts

Public ContactHitoshi Inafuku

University of the Ryukyus Hospital

hitoshiinafuku@yahoo.co.jp+81-98-895-1168

Outcome results